Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.

Expert opinion on investigational drugs - 1 Aug 2024

Amadeo Elisabeth, Foti Silvia, Camera Silvia, Rossari Federico, Persano Mara, Lo Prinzi Federica, Vitiello Francesco, Casadei-Gardini Andrea, Rimini Margherita

Abstract excerpt

INTRODUCTION: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the first for primary liver tumors. In recent years greater therapeutic advancement was represented by employment of tyrosine kinase inhibitors (TKIs) either in monotherapy or in combination with immune checkpoint inhibitors (ICIs). AREAS COVERED: Major attention was given to target therapies in the last couple of years,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Drug Development

Share to Immune Checkpoint Inhibitors

Share to Liver Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 39039690
DOI: 10.1080/13543784.2024.2377321

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.PMID 39039690Read ↗

Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.Semantic proximity Read ↗

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.Semantic proximity Read ↗

Targeted therapy for hepatocellular carcinoma: Challenges and opportunitiesSemantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.Semantic proximity Read ↗

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.Semantic proximity Read ↗

Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Non-coding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment ResponseSemantic proximity Read ↗

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.